REGORAFENIB |
BAY-734506 MONOHYDRATE |
STIVARGA |
BAY-73-4506 |
BAY-734506 |
RÉGORAFÉNIB |
STIVARGA® |
REGORAFENIBUM |
BAY 73-4506 |
chemidplus:755037-03-7 |
drugbank:08896 |
chembl:CHEMBL1946170 |
rxcui:1312397 |
pubchem.compound:11167602 |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Colorectal cancer, Gastrointestinal stromal tumors |
Drug Class | Kinase Inhibitors |
Drug Categories | bradycardia-causing agents |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | hepatotoxic agents |
Drug Categories | kinase inhibitor |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | tyrosine kinase inhibitors |
Drug Categories | ugt1a9 inhibitors |
Drug Categories | ugt1a9 substrates |
inhibitor (inhibitory) |
Mechanism of Interaction | Discoidin domain-containing receptor 2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | regorafenib, BAY 73-4506 |
Novel drug target | Novel Target |
Notes |
inhibitor (inhibitory) |
Response Type | decreased response |
Approval Status | Preclinical - Cell culture |
Approval Status | Phase II |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase RAF inhibitor |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | MAP kinase p38 beta inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase FRK inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Drug family | Pan-kinase inhibitor |
inhibitor (inhibitory) |
Trial Name | regorafenib, BAY 73-4506 |
Novel drug target | Established target |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
Notes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Notes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Fibroblast growth factor receptor 2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Fibroblast growth factor receptor 1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
REGORAFENIB | Generic Name |
STIVARGA | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Colorectal cancer, Gastrointestinal stromal tumors |
REGORAFENIB | DrugBank Drug Name |
755037-03-7 | CAS Number |
Stivarga | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | antineoplastic agents |
Drug Indications | antineoplastic agent |
Drug Class | small molecule |
FDA Approval | not approved |
REGORAFENIB | Primary Drug Name |
REGORAFENIB | Drug Generic Name |
STIVARGA | Drug Trade Name |
CHEMBL1946170 | ChEMBL Drug ID |
D09GDD | TTD Drug ID |
REGORAFENIB | GuideToPharmacology Ligand Name |